T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ECG
851
Everus Construction Group
ECG
$5.96B
| $57M | 0.01% |
343,681
+295,614
| +615% | +$43.3M |
|
852
Clear Secure
YOU
$4.14B
| $57M | 0.01% |
1,022,936
+768,745
| +302% | +$42M |
|
853
Veralto
VLTO
$23.4B
| $57M | 0.01% |
642,689
-181,991
| -22% | -$15.8M |
|
854
Teva Pharmaceutical Industries Limited
TEVA
$45.3B
| $56.9M | 0.01% |
1,679,152
+1,045,016
| +165% | +$34.8M |
|
855
Summit Therapeutics
SMMT
$12.5B
| $56.7M | 0.01% |
3,893,820
-4,384,039
| -53% | -$77.7M |
|
856
Corvus Pharmaceuticals
CRVS
$1.01B
| $56.6M | 0.01% |
3,789,126
+871,826
| +30% | +$12.1M |
|
|
BCAX
857
Bicara Therapeutics
BCAX
$1.27B
| $56.5M | 0.01% |
1,904,248
+528,050
| +38% | +$11.8M |
|
858
Primerica
PRI
$8.43B
| $56.4M | 0.01% |
198,509
+47,563
| +32% | +$13M |
|
859
Affiliated Managers Group
AMG
$9.45B
| $56.4M | 0.01% |
166,559
-17,062
| -9% | -$5.29M |
|
860
Neurocrine Biosciences
NBIX
$14.2B
| $56.2M | 0.01% |
333,749
+182,493
| +121% | +$27.1M |
|
861
Ollie's Bargain Outlet
OLLI
$5.08B
| $56.2M | 0.01% |
731,230
+310,355
| +74% | +$25.9M |
|
862
ACI Worldwide
ACIW
$4.93B
| $56.1M | 0.01% |
1,116,210
+21,845
| +2% | +$950K |
|
863
Ingevity
NGVT
$2.51B
| $55.8M | 0.01% |
747,488
+148,438
| +25% | +$10.7M |
|
864
The Ensign Group
ENSG
$10.3B
| $55.5M | 0.01% |
345,949
-962,286
| -74% | -$170M |
|
865
Lennox International
LII
$12.7B
| $55.2M | 0.01% |
96,317
+815
| +0.9% | +$415K |
|
866
Northern Trust
NTRS
$31.8B
| $54.7M | 0.01% |
314,903
+16,615
| +6% | +$2.74M |
|
867
Prudential Financial
PRU
$39.9B
| $54.7M | 0.01% |
506,839
+10,193
| +2% | +$1.04M |
|
868
Aaon
AAON
$7.02B
| $54.6M | 0.01% |
430,042
+290,924
| +209% | +$34.1M |
|
869
D-Wave Quantum Inc
QBTS
$6.46B
| $54.5M | 0.01% |
2,269,777
+1,859,467
| +453% | +$40.8M |
|
870
Visteon
VC
$2.32B
| $53.7M | 0.01% |
541,559
+96,317
| +22% | +$10.5M |
|
871
Kilroy Realty
KRC
$3.94B
| $53.7M | 0.01% |
1,432,052
-14,043
| -1% | -$477K |
|
872
Simpson Manufacturing
SSD
$7.16B
| $53.6M | 0.01% |
255,852
+50,316
| +24% | +$9.41M |
|
873
Oceaneering
OII
$4.6B
| $53.5M | 0.01% |
1,320,910
+25,665
| +2% | +$967K |
|
874
Cavco Industries
CVCO
$4.31B
| $53.2M | 0.01% |
86,552
-6,069
| -7% | -$3.22M |
|
875
Atlanta Braves Holdings Series B
BATRK
$3.47B
| $53M | 0.01% |
1,021,743
+972,029
| +1,955% | +$47.7M |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.